目的 探讨参仙升脉口服液联合环磷腺苷葡胺注射液治疗病态窦房结综合征的临床疗效。方法 将江苏省人民医院宿迁医院在2024年5月—2025年4月收治的病态窦房结综合征患者共计150例作为研究对象，所有患者按随机数字表法分为对照组和治疗组，75例/组。对照组静滴环磷腺苷葡胺注射液，2支/次溶于250 mL葡萄糖注射液稀释，1次/d。治疗组在对照组基础上口服参仙升脉口服液，2支/次，2次/d。两组的疗程为1个月。对比两组患者治疗前后的治疗效果、心率、窦房结功能、生活质量、血液流变学。结果 治疗后，对照组总有效率为84.00%，治疗组总有效率为94.67%，组间差异显著（P＜0.05）。两组治疗后的最低心率、最高心率、平均心率明显提高（P＜0.05），治疗组的最低心率、最高心率、平均心率明显高于对照组（P＜0.05）。两组治疗后窦房结的校正后恢复时间、传导时间均明显降低（P＜0.05），治疗组治疗后的窦房结的校正后恢复时间、传导时间均短于对照组（P＜0.05）。两组治疗后的生活质量指数（DLI）评分均升高（P＜0.05），且治疗组治疗后的DLI评分明显高于对照组（P＜0.05）。两组治疗后的高切全血黏度、红细胞压积、血浆比黏度均明显降低（P＜0.05），治疗组治疗后的高切全血黏度、红细胞压积、血浆比黏度低于对照组（P＜0.05）。结论 参仙升脉口服液联合环磷腺苷葡胺注射液可提高病态窦房结综合征的治疗效果，提高心率和生活质量，改善血液流变学和窦房结功能。

Objective To investigate the clinical efficacy of Shenxian Shengmai Oral Liquid combined with Meglumine Adenosine Cyclophosphate Injection in treatment of sick sinus syndrome. Methods A total of 150 patients with sick sinus syndrome admitted to Jiangsu Provincial (Suqian) Hospital from May 2024 to April 2025 were selected as the study subjects. All patients were divided into control group and treatment group using a random number table method, with 75 cases per group. The control group received intravenous infusion of Meglumine Adenosine Cyclophosphate Injection, two tubes per time, diluted in 250 mL glucose injection, once daily. The treatment group received oral administration of Shenxian Shengmai Oral Liquid on the basis of the control group, two tubes per time, twice daily. The treatment course was one month. The treatment effect, heart rate, sinoatrial node function, quality of life, and hemorheology were compared before and after treatment. Results After treatment, the total effective rate of the control group was 84.00%, and the total effective rate of the treatment group was 94.67%, with significant difference between two groups (P < 0.05). The minimum heart rate, maximum heart rate, and average heart rate of two groups were significantly increased after treatment (P < 0.05), and the minimum heart rate, maximum heart rate, and average heart rate of the treatment group were significantly higher than those of the control group (P < 0.05). After treatment, the corrected recovery time and conduction time of the sinoatrial node in two groups were significantly reduced (P < 0.05), and the corrected recovery time and conduction time of the sinoatrial node in the treatment group were shorter than those in the control group (P < 0.05). The quality of life index (DLI) scores of two groups increased after treatment (P < 0.05), and the DLI score of the treatment group was significantly higher than that of the control group after treatment (P < 0.05). After treatment, the high shear whole blood viscosity, hematocrit, and plasma specific viscosity of two groups were significantly reduced (P < 0.05), and the high shear whole blood viscosity, hematocrit, and plasma specific viscosity of the treatment group were lower than those of the control group (P < 0.05). Conclusion The combination of Shenxian Shengmai Oral Liquid and Meglumine Adenosine Cyclophosphate Injection can improve the therapeutic effect of sick sinus syndrome, increase heart rate, enhance quality of life, and improve hemorheology and sinus node function.

R972

宿迁市科技项目（SY202301）